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A B S T R A C T 
Gastrointestinal stromal tumor (GIST) is an uncommon neoplasm of GI tract with rectum being rare site. Biopsy of 
the lesion and immunohistochemistry (IHC) confirms the diagnosis. Complete surgical resection is the principal 
curative procedure. Chemotherapy with Imatinib alone show cure in intermediate risk rectal GIST. We describe a 
case of a 45-year-old male with per rectal bleeding and generalized weakness. CT scan revealed rectal mass with 
metastasis in the right lobe of the liver. Rectal biopsy revealed intermediate grade tumor GIST which was confirmed 
on IHC (CD117 and CD34). Imatinib chemotherapy alone had good symptomatic improvement at 4 months of 
follow up.  
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Introduction: Gastrointestinal stromal tumor (GIST) 
is  a  rare  tumor  involving  the  gastrointestinal  tract. 
Exact  epidemiological  data  of  incidence  and 
prevalence of GIST is not available due to lack of 
well  defined  pathologic  criteria,  various 
nomenclature  in  past    when  nearly  60%  of  all  the 
GIST  have  been  diagnosed  as  benign  tumors  or 
tumors of uncertain  malignant potential
1. 
 
By  definition  GIST  is  a  mesenchymal  neoplasm 
expressing KIT protein, driven by KIT or PDGFRα 
(platelet  derived  growth  factor  alpha)  mutations
2.
 
They are derived from interstitial cells of Cajal (ICC). 
ICC are pacemaker cells that regulates peristalsis and 
have immunophenotypic and ultrastructural features 
of both smooth muscle and neural differentiation in 
varying  degrees.  ICC  are  KIT  positive  cells. 
Activation  of  KIT  by  mutations,  causes  Cajal  cell 
proliferation and GIST
3. 
 
Stomach  is  the  common  site  for  GIST  (50–60%), 
followed  by  small  intestine  (30–40%),  colon  (7%) 
and  esophagus  (1%).  Rectum  is  the    rare  site  of 
GIST
4.  We  present  a  case  of  rectal  GIST,  with 
metastasis to liver treated by chemotherapy.  
 
Case  Details:  A  45-year-old  man  presented  to  our 
hospital  with  history  of  per  rectal  bleeding, 
generalized weakness and fever since 5 days. He was 
on  anti-koch’s  treatment  (AKT)  for  six  months  for 
rectal  tuberculosis  diagnosed  elsewhere.  However, 
details of that biopsy report were not available. The 
rectal examination showed two well defined masses 
one located at the right superior aspect and another 
located  at  left  lateral  aspect  of  the  rectal  wall. 
Routine blood tests were within normal limits. 
 
Plain CT scan revealed distension of rectum with two 
large polypoidal soft tissue attenuation lesions (Fig 1). 
Larger  mass  measured  9.1x8.7x5.2  cm,  located 
superiorly towards right and seen attached to superior 
wall.  The  smaller  lesion  measured  8x2x4  cm  and  
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seen placed lateral and inferior aspect. Post contrast 
image  revealed  heterogenous  enhancement  and 
variable areas of central necrosis with few calcified 
areas.  Liver  showed  a  2x2  cm  well  defined 
hypodense, hypoenhancing focal lesion in segment V 
of  right  lobe.(Fig  2)  There  was  no  significant 
lymphadenopathy  on  CT  scan.  Punch  biopsy  was 
taken from the rectal masses. 
 
Fig1. CT Abdomen-  showing distension of rectum 
with  large  polypoidal  soft  tissue  attenuation, 
heterogenous  enhancement  and  areas  of  central 
necrosis calcification 
 
  
Fig 2: CT Scan liver showing well defined hypodense, 
hypoenhancing  focal  lesion  in  segment  V  of  right 
lobe suggestive of metastasis 
 
  
Histological  examination  showed  rectal  tissue  with 
submucosal  tumor    location  composed  of 
proliferation of densely packed epitheloid and spindle 
cells,  with  prominent  nuclear  palisading  (Fig  3). 
Mitotic count was of 3 mitosis/50HPF. C-KIT protein 
(Fig  4)  and  CD34(Fig  5)  were  positive.  Final 
diagnosis was GIST of intermediate risk aggressive 
behavior(Table1)  with  metastasis  in  liver.  Patient 
underwent  chemotherapy  with  Imatinib  and 
defunctional  colostomy.  Postoperative  course  was 
uneventful.  The  patient  was  discharged  on 
postoperative  day  12.  Follow  up  at  4  months  with 
rectal  ultrasonography  and  CT  scan  showed 
significant reduction in size of tumor mass. 
 
Fig 3. Histopathology –High power  view -Tumour 
composed of proliferation of densely packed spindle 
cells, with nuclear palisading. (HE X400) 
  
 
Fig  4.  C-KIT  staining  in  GIST.  Cytoplasmic  and 
perinuclear strongly positive tumour cells (×400). 
                          
Fig 5. CD34 Positivity seen in tumor cells of GIST 
(IHCx 400) 
 
  
Discussion:  The  term  “GIST”  was  introduced  in 
1983. It included tumors of the GI tract that could not 
be classified as either smooth muscle or neurogenic 
in origin
5. Among GI mesenchymal tumors GISTs are 
the most common.  
 
→  
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Table  1:    Defining  risk  of  aggressive  behavior  in 
GIST 
12 
  Size  Mitotic Count 
Very low risk  < 2 cm  
 
 < 5/50 HPF 
 
Low risk  2–5 cm  
 
 < 5/50 HPF 
 
Intermediate 
risk  
 
< 5 cm  
 
6–10/50 HPF 
 
5–10 cm   < 5/50 HPF 
High risk  > 5 cm   > 5/50 HPF 
> 10 cm   Any mitotic rate 
Any size  
 
> 10/50 HPF 
 
GIST  is  an  uncommon  mesenchymal  tumor  and 
expresses  CD117,  a  tyrosine-kinase  growth  factor 
receptor as important marker.
5 CD117 also serves as 
the target for drug therapy with imatinib, a selective 
tyrosine-kinase receptor inhibitor that is at present the 
only  promising  chemotherapeutic  drug  for  the 
treatment of patients with advanced GIST, although 
complete  surgical  resection  remains  the  most 
effective treatment for such a tumor
10. The symptoms 
of GIST in the rectum do not generally differ from 
those of other rectal tumors and diagnostic work-up 
is  also  similar.  Digital  examination  of  the  rectum, 
colonoscopy and transrectal ultrasound are essential 
for diagnosis.Preoperative biopsy plays a key role in 
the diagnosis of GIST, since it provides information 
on  the  immunohistochemical  features  and  mitotic 
count. GIST typically expresses CD117, often CD34 
and sometimes SMA and S-100, but its expressions 
vary depending on different sites. Miettinen et al 
11 
found that CD34 expression in rectal GIST is 92%, 
but  only  50%  in  small  intestinal.  Smooth  muscle 
antigen (SMA) is most frequently seen in the small 
intestinal (47%) and only 14% of rectal GISTs. The 
reason for these variations remains explained. Most 
GISTs  originate  within  the  muscularis  propria  and 
most commonly have an exophytic growth pattern
12-
13,  seen  on  CT  and  MRI  images.  A  focal,  well-
circumscribed  mural  mass  is  the  most  common 
finding  and  an  infiltrated  layer  can  be  clearly 
assessed
6. CT or MRI helps define local invasion and 
detection of metastases. 
 
Because  of  low  incidence  the  clinicopathological 
profiles of rectal GIST have not yet been accurately 
characterized and prognostic factors of common sites 
like stomach is used instead.. Size and mitotic rate 
are  common  prognostic  criterias.
15-17  A  rate  of  ≤  5 
mitoses  per  50  HPF  is  taken  used  as  a  limit  to 
discriminate between benign and malignant.
4 Tumors 
of  2  cm  in  diameter  generally  behave  in  a  benign 
fashion.  Less than 5 cm in  diameter are associated 
with a better survival. The epithelioid phenotype has 
poor  outcome.  Symptoms  lasting  for  at  a  year  is 
considered as further prognostic factors. 
 
Complete surgical resection with negative margins is 
curative  for  primary  and  non-metastatic    low  risk 
tumors.
12,19-21  Local  excision,  anterior  resection  or 
abdomino-perineal resection for rectal GIST depends 
on tumor size and location
4,22. Neoadjuvant imatinib 
may  be  useful  in  inoperable  malignant  GIST  to 
optimize  surgical  timing.  Imatinib  is  useful  as 
adjuvant  post-operative  treatment    in  high  risk  or 
incomplete  surgical  resection.  Imatinib  is  accepted 
treatment  for  advanced  or  metastatic  tumors  but 
further evidence is  needed in the case of  high risk 
tumors and for the neoadjuvant therapy. 
 
Conclusion:  Rectal  GIST  tumoris  rare.  The 
diagnostic workup is same as other rectal neoplasia. 
Biopsy tumoris essential for preoperative diagnosis. 
Immunohistochemical characterisation of CD117 and 
CD34 are important tumor markers.  Further studies 
are  necessary  to  establish  extent  of  resection  and 
effective treatment strategy for rectal GIST.  
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